BFC Planning’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BFC Planning's ACAD Position: Q3 2026 in Review
BFC Planning opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 9 shares worth $181. The stake represents ﹤0.01% of the portfolio and ranks #3360 among its holdings. This is a return to the name: BFC Planning previously reported a position in ACAD as recently as Q4 2025.
BFC Planning first reported a position in ACAD in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.02K in Q4 2025. 263 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- BFC Planning held 9 shares of Acadia Pharmaceuticals worth $181 as of Q3 2026.
- Acadia Pharmaceuticals was a new BFC Planning position in Q3 2026.
- Acadia Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3360 holding.
- BFC Planning first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
- BFC Planning's Acadia Pharmaceuticals position peaked at $1.02K in Q4 2025.
- 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.